Pursuant to the provisions of Regulation 30 and other applicable provisions of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, ....
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
The board of Gian Life Care Ltd approved its unaudited financial results for the quarter and half year ended September 30, 2025. Standalone revenue from operations fell sharply to Rs. 66 lakhs in Q2 FY26 from Rs. 194.67 lakhs in Q2 FY25, and the company slipped into a loss of Rs. 40.75 lakhs (standalone) / Rs. 45.82 lakhs (consolidated) for H1 FY26, versus a profit in the prior year period. The auditor (MSNT & Associates LLP) issued a qualified review report, flagging that Rs. 743.78 lakhs of cash is sitting on the balance sheet while statutory dues of Rs. 426.66 lakhs and a bank loan of Rs. 359.78 lakhs (classified as NPA) remain unpaid. The auditor also could not physically verify the cash and was unable to confirm its existence and appropriateness. EPS turned negative at Rs. (0.40) standalone and Rs. (0.45) consolidated for H1 FY26.
This is a negative disclosure for shareholders. The combination of a steep revenue decline, a swing to losses, an NPA-tagged bank loan, unpaid statutory dues, and an auditor unable to verify the cash balance raises serious concerns about financial health and governance. Investors should expect stock price pressure and heightened scrutiny on the company's ability to continue as a going concern.